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AbstrACt
Introduction Depressive disorders are very common 
diseases entailing a great burden on affected people. 
However, comprehensive information on long- term disease 
course in patients with severe depression is lacking so 
far. The objectives of the DELTA study are to examine 
long- term outcomes and their predicting factors, to assess 
clinical response of antidepressant pharmacotherapy by 
applying therapeutic drug monitoring, to identify predictors 
of therapeutic non- response, to describe the long- term 
healthcare utilisation and to investigate the role of 
biomarkers in disease course.
Methods and analysis A cohort study including all 
adult hospitalised cases (age range 18 to 75 years) 
of severe major depression who are admitted to the 
Bezirkskrankenhaus Augsburg is established. It is 
planned to include 300 patients. During the hospital 
stay, information is gathered through personal interview, 
self- administered questionnaires, cognitive tests and 
chart review. Furthermore, biomaterials are collected. 
After hospital discharge, patients are repeatedly re- 
examined over time (3, 6, 12, 24 and 36 months) to collect 
information about mortality, relapse, depression severity, 
health- related quality of life (HRQOL), perceived stigma, 
cognitive functions, diet, physical activity, treatment 
and healthcare utilisation. Follow- up blood samples are 
collected to determine therapeutic drug levels. The primary 
study aim is to investigate long- term therapeutic response, 
survival, relapse, HRQOL and cognitive functions. Survival 
time and time to relapse or re- hospitalisation will be 
analysed using Cox regression models. Changes of HRQOL, 
depressive symptoms and cognitive functions over time 
will be examined using generalised linear regression 
models for repeated measures or mixed models. 
Correlates of the disease course will be modelled using 
suitable generalised linear, mixed, estimating equation and 
growth curve models.
Ethics and dissemination The study protocol was 
approved by the Ethics Committee of the Ludwig- 
Maximilians- Universität München (date of approval: 23 
October 2017, reference number: 17–625). Study results 
will be presented at scientific conferences and published 
in peer- reviewed scientific journals.
IntroduCtIon
Depressive disorders are very common 
diseases affecting 180 million people world-
wide.1 Data from Germany revealed a life- 
time prevalence of any depressive disorder 
(excluding depressive episodes in bipolar 
disorder) of 19% (women: 25%, men 12%) 
and a 12- months- prevalence of 12% in the 
general population aged 18 to 65 years. Severe 
depressions account for 30% of all cases.2 
Persons with depressive disorders suffer 
from a reduction of health- related quality of 
life (HRQOL)3–5 and impaired functioning, 
specifically regarding interpersonal activities 
and work.6 7 In particular, the large indirect 
costs associated with absenteeism from work, 
disability and mortality make depressive 
disorders the most costly mental disorders in 
Europe.8
Several studies have identified treatment 
deficits und unmet healthcare needs in 
persons with depressive disorders.2 9 10 A recent 
study using claims data from the German 
statutory health insurance showed that 18% 
of persons with a diagnosed severe major 
depression were not treated, and only 12% 
received a treatment according to the guide-
lines.11 In addition, since routine data from 
health insurance funds do not include infor-
mation on in- hospital treatment/medication 
strengths and limitations of this study
 ► This study considers a variety of outcomes, which 
are rarely included in clinical trials (eg, cognitive 
functions, health- related quality of life).
 ► A limitation of the study is that analyses are not 
based on randomised treatment assignments.
 ► Loss to follow- up may lead to biased results.
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of depression, profound scientific knowledge on this 
issue is lacking so far.12 Comprehensive data on health 
services use and real- life treatment in Germany based on 
large samples is missing. Insufficient healthcare, however, 
may contribute to unfavourable disease courses.13
Current national and international guidelines on treat-
ment of major depression have highlighted a number 
of future research needs.14 15 An important issue is the 
lack of longitudinal studies and knowledge on the contin-
uation and maintenance phase of treatment. Another 
research need refers to the unclear relation between 
medication blood levels and therapeutic response and 
the long- term attainment of therapeutic blood levels. In 
clinical practice, partial response and non- response to 
antidepressant pharmacotherapy are common.16 Thera-
peutic drug monitoring can be used to optimise antide-
pressant pharmacotherapy and to avoid side effects by 
tailoring the drug dosage to the individual characteristics 
of a patient.17 However, the benefit of this tool in routine 
patient care is so far not adequately assessed.14
In addition, guidelines encourage to further investi-
gate the role of complementary treatments in depres-
sion. Complementary and complementary medicine 
(CAM) is very popular in Germany.18 19 Only a few inter-
ventions have demonstrated therapeutic effectiveness in 
depression, for example, St John’s wort.20–22 However, it 
is unclear, how many patients use CAM in the years after 
hospital discharge, which CAM interventions they choose 
and which characteristics CAM users have.
In terms of outcomes of depression treatment, clinical 
trials primarily focus on symptom reduction as indica-
tors of therapeutic response. Other indicators such as 
HRQOL and cognitive functioning are so far only scarcely 
included into investigations on depressive disorders.23
Furthermore, it is so far unclear how patients who will 
respond to depression treatment differ from patients 
who will not respond. A number of social, mental, life-
style, physical and physiological characteristics may play a 
role. Current research has identified physical activity and 
diet as being related with the development and course 
of mental disorders24 and that physical activity and exer-
cise support the improvement of depressive disorders.25 
Detailed long- term analyses of the association of physical 
activity with relief of depressive symptoms and changes in 
HRQOL are, however, scarce. In addition, studies among 
older people have further suggested that there is a strong 
association between low muscle strength and depressive 
symptoms.26–28 However, studies addressing the relation-
ship between muscular strength and clinical status among 
hospitalised patients with depression are missing and the 
prognostic importance of muscular strength for clinical 
outcomes of these patients has not yet been investigated. 
In addition, diet and nutrition seem to play a crucial 
role in depression, as demonstrated by epidemiological 
studies and current randomised controlled trials.29 30
Increasingly, novel ‘-omics’ data (genomics, metabolo-
mics, proteomics) are being used as a tool for a better 
understanding of psychiatric disorders, including the 
discovery of biomarkers for diagnosis, monitoring of 
disease course and treatment response and the develop-
ment of more personalised treatment.31 32 Moreover, the 
gut microbiota is in the focus of current research. The 
bidirectional communication between the gut micro-
biota and the brain has been shown to influence neuro-
transmission and the behaviour that is often associated 
with neuropsychiatric conditions. Modulation of the 
gut microbiota through probiotic and prebiotic foods 
and supplements may be a novel therapeutic approach 
also in depressive disorders.33 34 In addition, examina-
tion of gut microbiota may facilitate the identification 
of patient subgroups according to disease development 
and response to pharmacological treatment. In these new 
research areas prospective studies are needed.34 35
objectives
The primary study aim is to investigate long- term thera-
peutic response, survival, relapse, HRQOL and cognitive 
functions. Secondary study objectives are (1) to describe 
long- term medication use and to assess clinical response 
and side effects of antidepressant pharmacotherapy by 
applying therapeutic drug monitoring, (2) to identify 
predictors of therapeutic non- response, (3) to examine 
the role of physical activity, grip strength and diet in 
disease course and outcomes, (4) to examine the asso-
ciation between cognitive/perceptual impairment and 
disease course and outcomes, (5) to describe the long- 
term healthcare utilisation and to determine differences 
in healthcare utilisation according to diagnosis, age, 
gender, socioeconomic status, social network and place 
of residence, (6) to investigate the use of complementary 
therapies and (7) to investigate the role of biomarkers 
analysed in different biospecimens (blood, urine, stool), 
for example, inflammatory parameters, metabolomics 
and proteomics data in disease course and outcomes.
MEthods And AnAlysIs
study design
The DELTA study is a single- centre, prospective cohort 
study. Patients are recruited from the Bezirkskranken-
haus (BKH) Augsburg, which offers in- hospital psychi-
atric healthcare for the study region covering the city 
and district of Augsburg (~400 000 adult inhabitants). 
All patients receive a baseline assessment during their 
hospital stay after verification of inclusion criteria and 
obtainment of informed consent. Subsequently, patients 
are contacted at 3, 6, 12, 24 and 36 months after discharge 
and invited to take part in follow- up examinations at 
the BKH Augsburg. Patient recruitment has started in 
February 2018 and the study will be finished in 2023.
Patient selection
Inclusion criteria
The study will include all consecutive patients (age 
18 to 75 years) with a primary discharge diagnosis of 
severe major depression (International Classification of 
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Diseases, Tenth Revision (ICD-10) codes: F32.2, F32.3, 
F33.2, F33.3) according to the Structured Clinical Inter-
view for DSM IV (SCID- I, categories A, B, C, D)36 criteria, 
with in- hospital treatment at the BKH Augsburg. Further-
more, a score ≥16 at the Hamilton Depression Rating 
Scale37 is required.
Exclusion criteria
Exclusion criteria are: (1) Mental and behavioural disor-
ders due to psychoactive substance use (F10 to F19), 
(2) disorders of adult personality and behaviour (F60 
to F60.9, F61) (3) mental retardation (F70 to F79), (4) 
dementia (F00 to F09), (5) insufficient knowledge of the 
German language, (6) comorbidities with a life expec-
tancy <1 year (eg, terminal cancer).
Measurements
Measurements take place in the hospital during the initial 
hospital stay and 3, 6, 12, 24 and 36 months after discharge 
(see table 1) and are conducted by well- trained psycholo-
gists and study nurses. The patients are contacted by study 
nurses by telephone in order to make an appointment for 
a follow- up examination.
Interview
After information and written consent of the patient, a 
standardised face- to- face baseline interview is performed 
in order to collect information on sociodemographic char-
acteristics, previous depressive episodes and concomitant 
disorders (eg, cardiovascular diseases, diabetes, cancer) 
and treatment and lifestyle factors such as smoking and 
alcohol consumption. The interview conducted at the 
follow- up visits additionally includes information on 
healthcare utilisation (readmissions, visits to physicians, 
psychotherapists, other health professionals, hospitals), 
use of complementary therapies, employment status, 
current medication and medication side effects.
Medical charts
Information on disease history, in- hospital treatment 
and medication are extracted from the patients’ medical 
records after discharge.
Clinical ratings
Disease severity is assessed by the study psychologists 
using the Hamilton Depression Rating Scale.37 38 In addi-
tion, symptoms of depression are self- rated by the patients 
using the Beck Depression Inventory.39
Self-adminstered questionnaires
Self- adminstered questionnaires are used to collect infor-
mation on HRQOL, diet, physical activity and perceived 
stigmatisation.
HRQOL is assessed by two different questionnaires. The 
WHOQOL- BREF is an instrument intended to measure 
quality of life according to the WHO definition that quality 
of life is the individuals perception of their position in life 
in the context of the culture and value systems in which 
they live and in relation to their goals, expectations, 
standards and concerns. It includes 24 items which cover 
the domains ‘Physical’, ‘Psychological’, ‘Social relation-
ships’ and ‘Environment’. The WHOQOL- BREF has 
been successfully applied in patients with depression and 
the German version has been validated in individuals with 
psychiatric disorders.40–43 The second questionnaire is the 
EQ- 5D- 5L, a generic instrument consisting of five items 
addressing mobility, self- care, usual activity, pain/discom-
fort and anxiety/depression and a visual analogue scale 
to assess general health.44 Psychometric properties of the 
German EQ- 5D have been evaluated across diseases and 
populations.45–48 The main advantage of the EQ- 5D- 5L is 
the availability of utility scores which enable the calcula-
tion of quality- adjusted life- years and the incorporation in 
health- economic analyses.49
A food frequency questionnaire is used to obtain data 
on the habitual diet.50 This questionnaire comprises ques-
tions on the frequency and portion size of 158 food items 
eaten during the year preceding hospital admission. It 
has been used in a large epidemiological study (Euro-
pean Prospective Investigation into Cancer and Nutrition 
(EPIC) trial) and the German version has been tested for 
its reproducibility and validity within this trial.50 51
Physical activity is measured by the International Phys-
ical Activity Questionnaire (IPAQ) 7- item short- form 
which is a well- validated and very common self- report 
instrument.52 53 The IPAQ has been successfully applied 
in studies on patients with major depression and bipolar 
disorder.54 55
The Internalised Stigma of Mental Illness (ISMI) scale 
is a 29- item questionnaire measuring self- stigma among 
persons with psychiatric disorders.56 Psychometric data 
are available from a number of studies demonstrating 
reliability and validity across a wide range of mental 
health conditions, languages and cultures.57 The German 
version of the ISMI scale has shown good psychometric 
properties with high internal consistency, good test- retest 
reliability and good construct validity among people with 
schizophrenia spectrum disorder.58
Tests and examinations
A subtest of the Wechsler Adult Intelligence Scale- IV 
— the digit span — is used to assess working memory.59 
Participants are verbally presented a series of two 
numbers which shall be recalled in forward, backward 
and sequential order. The number of digits in a series 
increase until the participant fails to correctly recall the 
series twice. Executive functions include semantic word 
fluency as assessed by the Regensburger Wortflüssigkeits- 
Test.60 The participant is asked to name as many different 
animals/foods as possible within 2 min. Furthermore, a 
version of the Stroop- Test (Farbe- Wort- Interferenztest) is 
used to assess executive functions.61 The participants are 
requested to read names of colours, to name the colour 
of colour samples and to name the printed colour of the 
colour names. In the last condition that represents an 
interference condition, the name of the colour is printed 
in a colour not denoted by the name. The processing 
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Table 1 Variables and measures
Collected variables Baseline 3 months 6 months 12 months 24 months 36 months
Interview
  Sociodemographic information x
  Employment status x x x x x x
  Smoking x x x x x x
  Alcohol consumption x x x x x x
  Disease history x x x x x x
  Comorbid conditions x x x x x x
  Healthcare utilisation x x x x x
  Current medication x x x x x x
  Medication side effects x x x x x
Medical chart
  Disease history x
  In- hospital treatment x
  In- hospital medication x
Clinical ratings
  Hamilton Depression Rating Scale37 38 x x x x x x
Self- administered questionnaires
  Depression: Beck Depression 
Inventory39
x x x x x x
  Health- related quality of life: WHOQOL- 
BREF40, EQ- 5D- 5L44
x x x x x x
  Stigmatisation: Internalised Stigma of 
Mental Illness56
x
  Diet: Food Frequency Questionnaire x x
  Physical Activity: International Physical 
Activity Questionnaire – short- form52
x x x x x x
Tests, examinations
  Memory: WechslerAdult Intelligence 
Scale- IV, subtest digit span59
x x x x x
  Semantic word fluency: Regensburger 
Wortflüssigkeits- Test60
x x x x x
  Executive functions: Farbe- Wort- 
Interferenztest according to J.R. 
Stroop61
x x x x x
  Olfactory functions: Sniffin sticks-1262 x x x x x
  Handgrip strength x x x x x x
  Body height x x x x x x
  Body weight x x x x x x
Biomaterial
  Blood sample for therapeutic drug 
monitoring (small, without storage)
x x x x x x
  Blood sample (large, with storage) x x
  Stool sample x x
  Urine sample x x
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time is documented as well as the number of corrected 
and uncorrected errors in the interference condition. It 
is also reported whether a repetition of a single condition 
was necessary.
Olfactory functions are assessed by the Sniffin‘ Sticks - 
Screening 12 test,62 63 a validated test for the screening of 
olfactory functioning. Twelve odorants are offered to the 
participants. The correct substance has to be chosen from 
a card displaying four different substances. Depending 
on the number of correctly recognised substances, the 
test is able to differentiate between anosmia, hyposmia 
and normosmia.
Handgrip strength is measured by means of the Jamar 
Plus Hydraulic Hand Dynamometer (device number: 
2016011210). The measurements are performed on the 
grip position 2 and the test modus LR1, which means that 
the left and right hand are tested in turn. Prior to that, 
participants are questioned about their preferred hand 
use and whether they are aware of any restrictions for 
the measurements to be carried out (eg, diseases, inju-
ries, inflammations or chirurgical operations of arms 
and hands). Measurements are carried out in a prede-
termined sitting position: Participants are instructed to 
grip the dynamometer as strongly as possible for 3 s and 
to breathe normally during this exertion. Each hand is 
tested three times in this fashion, starting with the left 
hand.
Body weight is measured during the baseline assess-
ment and all of the follow- up examinations. Participants 
are asked to remove their shoes and any heavy jackets, 
belts or heavy objects from their pockets. Additionally, 
body height is assessed once during participants’ involve-
ment in the study.
Biomaterial
Blood, stool (native and stabilised) and urine samples 
are collected within the DELTA study. Blood samples are 
collected in the morning, fasting and before medication 
intake. Biomaterial samples are processed and aliquoted 
into sample tubes at the BKH Augsburg, frozen at −80°C 
and stored in the biorepository of the Chair of Epide-
miology, UNIKA- T Augsburg. A sample of 30 mL blood 
is collected from the patients after study inclusion and 
1 year post discharge. In addition, during the hospital 
stay, after having reached a stability in terms of medica-
tion management and close to the date of discharge and 
at each follow- up visit, a second, smaller blood sample is 
collected and analysed for serum or plasma drug concen-
tration. Results of the therapeutic drug monitoring are 
forwarded to the patients’ prescribing physician, in order 
to enable a dose modification to reach therapeutic drug 
levels.
Mortality follow-up
Regular mortality follow- ups are performed using infor-
mation from the residents’ registration offices in the 
study area. Causes of death are extracted from the death 
certificates provided by the local health authorities in the 
study region and are coded by a trained person according 
to ICD-10.
Quality assurance
Quality assurance (QA) will be based on the ‘Guidelines 
and Recommendations for Good Epidemiological Prac-
tice’ from the German Society of Epidemiology64 and 
the guideline for adaptive management of data quality 
in cohort studies and registries published by TMF (Tech-
nologie- und Methodenplattform für die vernetzte mediz-
inische Forschung e.V.).65
Prior to the start of the main study all applied methods 
and procedures were tested in five pilot patients. Stan-
dard operating procedures were established for all rele-
vant operations. Study nurses and psychologists received 
a training prior to the start of the study and will receive 
ongoing training and yearly recertification. Particularly, 
study psychologists received a rater training for SCID and 
Hamilton Depression Rating Scale by an experienced 
psychiatrist.
Recruitment rates will be continuously monitored and 
QA of scientific data (eg, plausibility, completeness) will 
be regularly performed by the data managers.
statistical analysis
Analyses of data plausibility, completeness, distribution, 
concordance and accuracy will be performed in order to 
ensure data quality. In order to estimate bias due to loss to 
follow- up, baseline date of complete cases and cases lost 
to follow- up will be compared. Descriptive statistics will 
be used to describe medication use and side effects, drug 
concentrations, healthcare utilisation, use of complemen-
tary therapies, etc. Survival time and time to relapse or 
re- hospitalisation will be analysed using Cox regression 
models. Health services utilisation, including outpatient 
visits after discharge from hospital and re- hospitalisa-
tions, will be examined using Poisson regression models. 
Changes of HRQOL, depressive symptoms and cognitive 
functions over time will be examined using generalised 
linear regression models for repeated measures or mixed 
models if appropriate. Correlates of the disease course 
will be modelled using suitable generalised linear, mixed, 
estimating equation and growth curve models. Covariate 
selection will be performed using directed acyclic graphs 
and related methods.
sample size estimation
Every year, about 300 patients with severe depression 
receive in- hospital treatment at the BKH Augsburg. Based 
on the experience from previous studies, it is expected 
that 50% of the patients will take part in the study and 
50% will be lost to follow- up. Consequently, it is planned 
to recruit about 300 study participants within 2 years and 
have available follow- up information on 150 patients. A 
sample size estimation for the primary study objective (to 
identify subgroups of treatment response) indicated that 
data from 126 participants are needed given an effect size 
of 0.25, α of 0.05 and β of 0.95.
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Ethics and dissemination
The study is performed according to the Declaration of 
Helsinki. Written, informed consent is obtained from 
the study participants. Patients who do not consent will 
not be included. The study results will be presented at 
national and international conferences and published in 
peer- reviewed scientific journals.
Patient and public involvement
Public and patients were not involved in development 
of the study design, in recruitment of study participants 
or the implementation of the study. However, the study 
results will be discussed using focus groups consisting of 
patients and healthcare providers.
dIsCussIon
This paper describes the study design of the DELTA 
study, a cohort study evaluating the long- term outcomes 
of patients with severe depression. The DELTA study is 
unique in a multifold way.
First, as an observational study, it offers a real- life view 
in the disease course of patients with severe depression 
beyond the inherent restrictions of clinical trials. It is 
possible to investigate a variety of outcomes, which are 
essential from the patient perspective (eg, HRQOL, 
cognitive functions), but are rarely included as outcomes 
in clinical trials.
Moreover, results from the DELTA study may improve 
the understanding of non- response to antidepressive 
treatment, since a number of potential factors that may 
contribute to response or non- response are investigated. 
These factors include novel ‘-omics’ data (metabolomics, 
proteomics) and the gut microbiota, which may play 
an important role for the personalisation of depression 
treatment in the future.
In addition, the DELTA study, which follows the 
participants for 3 years, is able to provide information 
on long- term adherence to antidepressive medication 
and treatment response. Comprehensive information 
on healthcare utilisation and treatments beyond phar-
macological therapy, including CAM interventions, is 
collected and may elucidate strengths and weaknesses of 
the healthcare offered to patients with severe depression 
in the study region.
In summary, the DELTA study is expected to contribute 
to the evidence regarding the long- term disease course 
and healthcare utilisation in patients with severe depres-
sion. The results can be an important basis for clinicians, 
administrators and health policymakers to improve 
healthcare in patients with this disorder.
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